Estimating health state utilities in primary hyperoxaluria type 1: a valuation study

References

• Lorenzo V, Torres A, Salido E. Primary hyperoxaluria. Nefrologia. 2014;34(3):398–412.
   PubMed Web of Science ®Google Scholar
• Milliner DS, McGregor TL, Thompson A, et al. End points for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol. 2020;15(7):1056–1065.
   PubMed Web of Science ®Google Scholar
• Primary hyperoxaluria. Danbury (CT): National Organization for Rare Disorders; 2020. Available from: https://rarediseases.org/rare-diseases/primary-hyperoxaluria/
   Google Scholar
• Milliner DS, Harris PC, Cogal AG, et al. Primary hyperoxaluria type 1. Seattle (WA): University of Washington, Seattle; 1993 [updated 2017 Nov 30]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1283/
   Google Scholar
• Harambat J, Fargue S, Acquaviva C, et al. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int. 2010;77(5):443–449.
   PubMed Web of Science ®Google Scholar
• Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369(7):649–658.
   PubMed Web of Science ®Google Scholar
• Lieske JC, Monico CG, Holmes WS, et al. International registry for primary hyperoxaluria. Am J Nephrol. 2005;25(3):290–296.
   PubMed Web of Science ®Google Scholar
• Ben-Shalom E, Cytter-Kuint R, Rinat C, et al. Long-term complications of systemic oxalosis in children–a retrospective single-center cohort study. Pediatr Nephrol. 2021;36(10):3123–3132.
   PubMed Web of Science ®Google Scholar
• Cochat P, Hulton SA, Acquaviva C, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27(5):1729–1736.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves first drug to treat rare metabolic disorder [press release]. U.S. Food and Drug Administration; 2020 [cited 2020 Nov 23]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-rare-metabolic-disorder
   Google Scholar
• Oxlumo (lumasiran): an overview of Oxlumo and why it is authorised in the EU. Amsterdam: European Medicines Agency; 2020 [cited 2020 Nov]. Available from: https://www.ema.europa.eu/en/documents/overview/oxlumo-epar-medicine-overview_en.pdf
   Google Scholar
• KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
   PubMed Web of Science ®Google Scholar
• Lawrence JE, Wattenberg DJ. Primary hyperoxaluria: the patient and caregiver perspective. Clin J Am Soc Nephrol. 2020;15(7):909–911.
   PubMed Web of Science ®Google Scholar
• Devresse A, Cochat P, Godefroid N, et al. Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep. 2020;5(12):2136–2145.
   PubMed Web of Science ®Google Scholar
• Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020;104(4S1 Suppl 1):S11–S103.
   PubMedGoogle Scholar
• Xiang J, Chen Z, Xu F, et al. Outcomes of liver-kidney transplantation in patients with primary hyperoxaluria: an analysis of the scientific registry of transplant recipients database. BMC Gastroenterol. 2020;20(1):208.
   PubMed Web of Science ®Google Scholar
• Jamieson NV, European PHI Transplantation Study Group. A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 transplant registry experience 1984–2004. Am J Nephrol. 2005;25(3):282–289.
   PubMed Web of Science ®Google Scholar
• Shee K, Stoller ML. Perspectives in primary hyperoxaluria – historical, current and future clinical interventions. Nat Rev Urol. 2022;19(3):137–146.
   PubMed Web of Science ®Google Scholar
• van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–715.
   PubMed Web of Science ®Google Scholar
• Lugnér AK, Krabbe PFM. An overview of the time trade-off method: concept, foundation, and the evaluation of distorting factors in putting a value on health. Expert Rev Pharmacoecon Outcomes Res. 2020;20(4):331–342.
   PubMed Web of Science ®Google Scholar
• Devlin NJ, Tsuchiya A, Buckingham K, et al. A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach. Health Econ. 2011;20(3):348–361.
   PubMed Web of Science ®Google Scholar
• Robinson A, Spencer A. Exploring challenges to TTO utilities: valuing states worse than dead. Health Econ. 2006;15(4):393–402.
   PubMed Web of Science ®Google Scholar
• Janssen BM, Oppe M, Versteegh MM, et al. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ. 2013;14(S1):5–13.
   PubMedGoogle Scholar
• Primary Hyperoxaluria Europe. Patient reports. Primary Hyperoxaluria Europe; 2022. Available from: https://www.ph-europe.net/#news1-section
   Google Scholar
• Alnylam Pharmaceuticals Inc. The Cataldo family – John’s diagnosis, dialysis and transplant story. Alnylam Pharmaceuticals Inc.; 2020. Available from: https://www.youtube.com/watch?v=w01RSJbEW2Q
   Google Scholar
• Nissel R, Latta K, Gagnadoux MF, et al. Body growth after combined liver-kidney transplantation in children with primary hyperoxaluria type 1. Transplantation. 2006;82(1):48–54.
   PubMed Web of Science ®Google Scholar
• CheckRare. Growing up with a rare kidney disease. CheckRare; 2021. Available from: https://www.youtube.com/watch?v=Y70sAr4YGKc
   Google Scholar
• Alnylam Pharmaceuticals Inc. Oxalate and the kidneys: primary hyperoxaluria in practice. Alnylam Pharmaceuticals Inc.; 2021 [cited 2021 Feb 19]. Available from: https://www.youtube.com/watch?v=jRG7BaSd_lY&list=PLCHQLbyuZK3ndyCim9GuFpL8033lmx51i&t=1558s
   Google Scholar
• Alnylam Pharmaceuticals Inc. Caregiving perspectives: Natalie & Jared, primary hyperoxaluria type 1 (PH1). Alnylam Pharmaceuticals; 2018 [cited 2018 Nov 12]. Available from: https://www.youtube.com/watch?v=PgQ3yUCZkxg&list=PLCHQLbyuZK3ndyCim9GuFpL8033lmx51i&t=32s
   Google Scholar
• Oxalosis and Hyperoxaluria Foundation. Every action has a reaction–where do you fit in? Oxalosis and Hyperoxaluria Foundation; 2019 [cited 2019 Jun 21]. Available from https://www.facebook.com/TheOHF/videos/410825166186442/?t=367
   Google Scholar
• Office for National Statistics website. Office for National Statistics; 2022 [cited 2022]. Available from: https://www.ons.gov.uk/
   Google Scholar
• Adult health in Great Britain, 2013. Office for National Statistics; 2015 [cited 2015 Mar 19]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/compendium/opinionsandlifestylesurvey/2015-03-19/adulthealthingreatbritain2013
   Google Scholar
• Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316(7133):736–741.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Aggio D, Slocomb TL, et al. Estimation of the quality-of-life impact of X-linked myotubular myopathy. J Neuromuscul Dis. 2021;8(6):1047–1061.
   PubMedGoogle Scholar
• Brazier J, Ara R, Azzabi I, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report. Value Health. 2019;22(3):267–275.
   PubMed Web of Science ®Google Scholar
• Clinical study protocol amendment: ILLUMINATE‐A: a phase 3 randomized, double‐blind, placebo‐controlled study with an extended dosing period to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 NCT03681184. ClinicalTrials.gov; 2019 [cited 2019 Mar 19]. Available from: https://clinicaltrials.gov/ProvidedDocs/84/NCT03681184/Prot_000.pdf
   Google Scholar
• Clinical study protocol: ILLUMINATE-C: a single arm study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) NCT04152200. ClinicalTrials.gov; 2020 [cited 2020 May 6]. Available from: https://clinicaltrials.gov/ProvidedDocs/00/NCT04152200/Prot_000.pdf
   Google Scholar
• Slade A, Isa F, Kyte D, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):61.
   PubMedGoogle Scholar
• Brazier J, Rowen D. NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values. London: National Institute for Health and Care Excellence; 2011.
   Google Scholar